Company intelligence / Profile preview

Calliditas Therapeutics AB

Ownership: Public · CALT
Employees: ~222
Development stage: Other

Overview

Calliditas received full FDA approval for TARPEYO in December 2023 for reducing kidney function loss in IgA nephropathy patients. Their setanaxib program showed mixed results in a Phase 2 head and neck cancer trial in May 2024, missing its primary endpoint but showing potential survival benefits. Phase 2b data for setanaxib in primary biliary cholangitis is expected in Q3 2024.

Therapeutic areas: GastroenterologyOncologyPulmonologyNephrology
Modalities: Small moleculesControlled-release drug formulationsNOX enzyme inhibitors
Industry: Biotech

Drug pipeline

5 assets

nefecon

Approved

4 more assets in the full pipeline.

Partnerships

Everest Medicines (China)STADA (EU)Viatris (Japan)

Beyond the preview

Go deeper on Calliditas Therapeutics AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calliditas Therapeutics AB.